LONDON, Jul. 16, 2007 (AFX International Focus) -- Northwest Biotherapeutics Inc (OTCBB:NWBO) refuted 'certain media reports' which claimed that it has received a market authorization for its therapeutic brain cancer vaccine from the Swiss authorities.
However, the company plans to apply for marketing authorization for the vaccine by the end of this year, adding the process of this fulfilment is under way.
The authorization will allow the company to export patients' immune cells and tumour tissue for vaccine manufacturing in the US, and import the patients' brain finished vaccine into Switzerland, the company added.
The company has also rejected media reports which 'erroneously' stated that its shareholders Toucan Capital and/or Toucan Partners have sold shares at the time of financing, adding such reports are incorrect.
Copyright AFX News Limited 2007. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
Newstex ID: AFX-0013-18154807